Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
-Medical News
 Blood Safety News
 NHF and Community News
 Industry News
 Travel Advisory

 

 

 
Novelos Seeks IND Status for New Hepatitis Drug
 

Novelos Therapeutics, a biotechnology company based in Boston, MA, has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) for its new hepatitis C drug, NOV-205. This product is a potential treatment alternative for the approximately 50% of chronic hepatitis (HCV) patients who do not respond to standard pegylated interferon and ribavirin therapy. NOV-205 has already gone through clinical studies and received regulatory approval in Russia. Novelos hopes to replicate the positive results achieved in the Russian trials by demonstrating safety and efficacy in the U.S. It plans to begin a clinical trial for NOV-205 by mid-2006.

Source: Novelos news release dated March 22, 2006

 

This section of our Web site is sponsored by: